ClinicalTrials.gg

Program

MK-6194

A development code.

Its studies are mostly in Lupus Erythematosus, Systemic · Vitiligo · Colitis, Ulcerative · Dermatitis, Atopic, led by Merck.

Furthest: phase 2, since Oct 27, 20236 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck60 open or runningphase 2since Oct 27, 2023Feb 26, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 26, 2021First study: phase 1 study in Colitis, UlcerativeFirst studyNCT04924114 · 57 enrolled · United States, Georgia, Germany and more
  2. Jul 5, 2022Phase 1 study in Dermatitis, AtopicNCT05450198 · 72 enrolled · United States, Belgium, Bulgaria and more
  3. Oct 27, 2023Phase 2 study in Non-segmental VitiligoNCT06113328 · 169 enrolled · United States, Argentina, Australia and more
  4. Nov 29, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT06161116 · 149 enrolled · United States, Argentina, Brazil and more
  5. Oct 17, 2024Phase 1 study in HealthyNCT06649877 · 16 enrolled · United States
  6. Feb 10, 2025Phase 1 study in HealthyNCT06821334 · 37 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06821334Healthy · China1CompletedAug 9, 202437
NCT06649877Healthy · United States1CompletedJul 13, 202316
NCT06161116Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more2TerminatedJul 30, 2025149
NCT06113328Non-segmental Vitiligo · United States, Argentina, Australia and more2TerminatedMar 20, 2025169
NCT05450198Dermatitis, Atopic · United States, Belgium, Bulgaria and more1CompletedMay 22, 202472
NCT04924114Colitis, Ulcerative · United States, Georgia, Germany and more1CompletedJan 8, 202457

How it is read

Names in the registry

  • “MK-6194”, 6 entries

Codes read as this program: MK6194.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.